Skip to main content
The Official Meeting of
Oncology Learning Network
+
Available Dates
See You Next Year!
The Official Meeting of
Oncology Learning Network
Agenda
Agenda
See You Next Year!
Register
See You Next Year!
Scroll previous
Friday
January 30
Saturday
January 31
Sunday
February 1
Scroll next
Friday January 30, 2026
8:40 AM – 10:15 AM
Leukemia Landscape: Emerging Data and Clinical Impact (Part 1)
Room
Talbot ABC
8:40 AM – 9:00 AM
Newly diagnosed AML: Does the Newest Data Support 7+3?
9:00 AM – 9:20 AM
Updates in Targeted Triplet Induction Regimens in AML for 2026 Practice
9:20 AM – 9:40 AM
Evolving Clinical Applications: The Expanding Role of MRD in AML
9:40 AM – 10:00 AM
Who Should Be Transplanted in AML? Evolving Criteria and New Evidence
10:00 AM – 10:15 AM
Question & Answer Panel
10:20 AM – 11:20 AM
Non-Accredited Innovation Theater/ Symposium (Sponsored by Abbvie)
Room
Talbot FH
Talk title: From Evidence to Action: A Case-Based Approach to Collaborative BCL2-Inhibitor Management in AML
Speaker: James M. Foran, MD
11:20 AM – 1:20 PM
Leukemia Landscape: Emerging Data and Clinical Impact (Part 2)
Room
Talbot ABC
11:20 AM – 11:40 AM
Myelodysplastic Syndromes (MDS): New Data and Evolving Treatment Paradigms
11:40 AM – 12:00 PM
Updates in Myeloproliferative Neoplasms: Translating Emerging Evidence into Practice
12:00 PM – 12:20 PM
Evolving Management of ALL: Integrating 2025 Data into 2026 Practice
12:20 PM – 12:35 PM
Question & Answer Panel
12:35 PM – 1:20 PM
Real Cases, Real Decisions: Turning Evidence Into Expertise
1:25 PM – 2:25 PM
Non-Accredited Innovation Theater (Sponsored by Lilly)
Room
Talbot FH
Talk title: See how Jaypirca® (pirtobrutinib) is sparking excitement
Speaker: Dr. Raji Shameem
2:25 PM – 2:55 PM
Exhibit Hall
2:55 PM – 4:55 PM
Lymphoma Landscape: Emerging Data and Clinical Impact (Part 1)
Room
Talbot ABC
2:55 PM – 3:15 PM
Updates in Upfront Diffuse Large B-cell Lymphoma (DLBCL) Informed by 2025 Data
3:15 PM – 3:35 PM
New Therapy Options in Relapsed Refractory DLBCL
3:35 PM – 3:55 PM
Current Approaches in Mantle Cell Lymphoma
3:55 PM – 4:10 PM
Question & Answer Panel
4:10 PM – 4:55 PM
Real Cases, Real Decisions: Turning Evidence Into Expertise
5:00 PM – 6:00 PM
Non-Accredited Sponsored Session
Room
Talbot FH
Talk title: From Today to Tomorrow: The Evolving Clinical Role of CELMoD Agents in Multiple Myeloma
Speakers: Dr. Sikander Ailawadhi; Dr. Mansi Shah
6:00 PM – 6:45 PM
Exhibit Hall Reception
Saturday January 31, 2026
8:40 AM – 10:15 AM
Lymphoma Landscape: Emerging Data and Clinical Impact (Part 2)
Room
Talbot ABC
8:40 AM – 9:00 AM
Waldenström’s Macroglobulinemia Management: What’s New and What’s Next
9:00 AM – 9:20 AM
The Latest Updates in Follicular Lymphoma
9:20 AM – 9:40 AM
Marginal Zone Lymphoma: Advancing Toward 2026 with New Clinical Insights
9:40 AM – 10:00 AM
My Evolving Approach to Hodgkin Lymphoma: Lessons from 2025 Data
10:00 AM – 10:15 AM
Question & Answer Panel
10:15 AM – 10:45 AM
Exhibit Hall
10:45 AM – 12:20 PM
CLL Landscape: Emerging Data and Clinical Impact (Part 1)
Room
Talbot ABC
10:45 AM – 11:05 AM
Updates in BTKi + BCL2i Combinations
11:05 AM – 11:25 AM
Updates in Management of BTKi Resistance and Mutations
11:25 AM – 11:45 AM
Continuous versus Fixed Duration Therapy Including Lessons from 2025 Data
11:45 AM – 12:05 PM
BTK Degraders: Emerging Clinical Data and What Lies Ahead
12:05 PM – 12:20 PM
Question & Answer Panel
12:25 PM – 1:25 PM
Non-Accredited Innovation Theater/ Symposium (Sponsored by Abbvie)
Room
Talbot FH
Talk title: Exploring BCL2i-based Time-Limited Regimens Throughout the CLL Journey
Speaker: Elizabeth Osmon, PharmD, BCPS, BCOP
1:25 PM – 3:25 PM
CLL Landscape: Emerging Data and Clinical Impact (Part 2)
Room
Talbot ABC
1:25 PM – 1:45 PM
Richter Transformation - What is New?
1:45 PM – 2:05 PM
Bispecifics versus CAR T Cell - The Roadmap for 2026
2:05 PM – 2:25 PM
The Next Frontier: What’s Left to Learn After the Latest Global Update
2:25 PM – 2:40 PM
Question & Answer Panel
2:40 PM – 3:25 PM
Real Cases, Real Decisions: Turning Evidence Into Expertise
3:25 PM – 3:55 PM
Exhibit Hall
3:55 PM – 4:55 PM
Chair Perspectives Beyond the Updates: What's Next in Hematology
Panelist
John Leonard
MD
Gail Roboz
MD
Richard Furman
MD
Ruben Niesvizky
MD
5:00 PM – 6:00 PM
Non-Accredited Innovation Theater (Sponsored by GSK)
Room
Talbot FH
Talk title: A New Treatment Option in Multiple Myeloma
Speaker: Radhakrishnan Ramchandren, MD
6:00 PM – 7:30 PM
Outdoor Welcome Reception
Sponsored by Takeda
Sunday February 01, 2026
8:05 AM – 8:55 AM
Myeloma Landscape: Emerging Data and Clinical Impact (Part 1)
Room
Talbot ABC
8:05 AM – 8:25 AM
What’s new in Front Line Treatment for Transplant Eligible Patients -Auto or CART?
8:25 AM – 8:45 AM
The Future of Frontline Treatment for Transplant-Ineligible Patients: Bispecifics vs. CAR T
8:45 AM – 8:55 AM
Question & Answer Panel
9:00 AM – 10:00 AM
Non-Accredited Innovation Theater (Sponsored by Regeneron)
Room
Talbot FH
Talk title: Explore a treatment option for your patients with R/R multiple myeloma
Speaker: Mansi Shah, MD
10:00 AM – 12:00 PM
Myeloma Landscape: Emerging Data and Clinical Impact (Part 2)
Room
Talbot ABC
10:00 AM – 10:20 AM
From 2025 Discoveries to 2026 Practice: Evolving Strategies in Early Relapsed Myeloma
10:20 AM – 10:40 AM
Beyond the Triple-Class Barrier: Emerging Strategies and Real-World Insights in Relapsed Myeloma
10:40 AM – 11:00 AM
New Molecules in Refractory Myeloma (CelMoDs & iMIDS) - Updates from 2025
11:00 AM – 11:15 AM
Question & Answer Panel
11:15 AM – 12:00 PM
Real Cases, Real Decisions: Turning Evidence Into Expertise
12:05 PM – 1:05 PM
Non-Accredited Innovation Theater (Sponsored by Johnson & Johnson)
Room
Talbot FH
Talk title: Making the Case for Early Use of CAR-T Therapy in Multiple Myeloma
Speaker: Marco Davila, MD, PhD
1:05 PM – 1:55 PM
Myeloma Landscape: Emerging Data and Clinical Impact (Part 3)
Room
Talbot ABC
1:05 PM – 1:25 PM
Who Will We Treat in 2026? High-Risk Smoldering Limited vs Full-Quad Treatment
1:25 PM – 1:45 PM
Gaps in Care: Extramedular, CNS Disease, and Plasma Cell Leukemia
1:45 PM – 1:55 PM
Question & Answer Panel
Back to top